RxDoctor Payments DataLook up a doctor →

Julio Navarro, MD

Family Medicine · Wilmington, DENPI 1689684581

Payments from drug & device makers

$13,081in general payments, 2019–2025

Across 732 payments — averaging $17.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Lilly USA, LLC$2K
  • Novo Nordisk$988
  • Pfizer$845
  • GSK$752
  • Amgen$742
  • plus $6K from 47 others

What the payments were for

  • Travel & lodging$901%
  • Food & beverage$12,90699%
  • Education$851%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,081 in reported general payments places this provider in the 95th percentile of 352 family medicine providers in Delaware.

See all family medicine providers in Delaware

Medicare billing

Part B allowed, 2024
$112,173
Medicare patients
151
Services billed
1,621

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OxycontinOxycodone Hcl14$60,954
TrulicityDulaglutide27$57,856
Trelegy ElliptaFluticasone/Umeclidin/Vilanter34$47,829
OzempicSemaglutide28$41,945
MounjaroTirzepatide19$35,371
EliquisApixaban15$18,938
JardianceEmpagliflozin11$18,630
Hydromorphone ErHydromorphone Hcl12$9,848
Rosuvastatin Calcium328$6,620
Oxycodone Hcl164$4,910
ShingrixVaricella-Zoster Ge/As01b/Pf20$4,432
Lantus SolostarInsulin Glargine,hum.Rec.Anlog18$4,375
VyvanseLisdexamfetamine Dimesylate11$4,007
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen107$3,038
Fentanyl27$2,439

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$1,675$93,22746 claims
GSKTrelegy Ellipta, Shingrix$752$52,26154 claims
Novo NordiskOzempic$988$41,94528 claims
PfizerEliquis$845$18,93815 claims
Boehringer IngelheimJardiance$148$18,63011 claims
Takeda Pharmaceuticals U.S.A., Inc.Vyvanse$62$4,00711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 352 family medicine providers in Delaware.

Other family medicine in Wilmington

See the full list for Delaware

Where these figures come from

Is this you, or does something look wrong? →